Subtitling Workshop at Translation Forum Discusses Subtitling Strategies, Constraints    Ministry of Health Reports 38 New COVID-19 Cases, 24 Recoveries in Saudi Arabia    Experts in the Field of Interpreting Advocate for New Interpreters to Attend Training Courses    Biden blasted for reviving Trump's inhumane Remain in Mexico policy    Biden tightens travel rules amid new Omicron cases    Germany slaps major Covid restrictions on unvaccinated    Covid risk remains higher for some ethnic groups, says report    King Salman Urban Charter initiative launched in Riyadh    UNESCO praises Madrasati's platform success as 'globally innovative educational model'    UNWTO names Rijal Almaa as one of 'best tourism villages' worldwide    FIA delivers seal of approval for Jeddah corniche circuit Final inspection of F1's newest circuit completed on Thursday    Remote Interpreting, Conference Interpreting, Applications of Political Translation Workshops Held to Develop Participants Skills    OIC Secretary General, Russian Permanent Representative Discuss Enhancing Cooperation    Blink Experience Becomes Official Supporter of Formula 1 STC Saudi Arabian Grand Prix 2021    Turkey's finance minister resigns amid currency crisis    Saudi Industrial Development Fund participates in Inlet Europe forum in Italy    Danube hosts 'Racing Kitchen' event with F1 Champion    Saudi Stock Exchange Main Index Ends Trading Higher at 10,882 Points    It's time for green health    British Consulate celebrates with grandeur Saudi Arabia's debut hosting of Formula 1 Grand Prix    India confirms 2 omicron variant cases    SFDA Participates in the Annual Summit of Alliance of Drug Regulatory Authorities    Duchess of Sussex wins latest court battle with Mail on Sunday publisher    Russia Records 33,389 New Cases of COVID-19, 1,221 Deaths    WTA suspends China tournaments over Peng Shuai case    Saudi chief of staff meets US Navy commander    Trolls join UN campaign for healthier eating, sustainable living    Riyadh Season draws over 4.5 million visitors in a month    Saudi Arabia Pavilion at Expo 2020 Dubai Highlights Saudi Cinema    BIENALSUR Exhibition arrives in Jeddah at historic site of Qasr Khuzam    Executive Committee of Hail International Rally 2021 Reviews Preparations for the Race    Saudi Stock Exchange Main Index Ends Trading Higher at 10,849 Points    Neom, Volocopter Establish Joint Venture to Create World's First Bespoke Public Evtol Mobility System    New data shows devastating impact of COVID on cancer treatment in Europe    Saudi Hind Al-Showaier Elected Regional Director of World Federation of the Deaf    Saudi Film Commission launch its strategy to develop film and cinema sector    Saudi Arabian Grand Prix Attracts World Attention to Jeddah Corniche Circuit    Bollywood superstar Salman Khan to dazzle Riyadh Season on Dec. 10    President, CEO of Saudi Arabian Fencing Federation to Participate in International Fencing Federation Congress    First Full International Marathon in Saudi Arabia to be Held in March 2022    Winter Wonderland Circus Amazes Audience with Thrilling Acrobatic Shows    Bollywood star's 'India got freedom in 2014' remark stirs controversy    23 Saudi women obtain favorable verdicts in 'adhl' lawsuits    Bride's fingerprint not required in revised e-marriage contract    Pilgrims Perform Dhuhr and Asr Prayers at Arafat Holy Site    Council of Senior Scholars: Muslim Brothers' Group Don't Represent Method of Islam, rather only Follows its Partisan Objectives, Violating our Graceful Religion    Eid Al-Adha Prayer Performed at the Grand Holy Mosque    Pilgrims Perform Dhuhr and Asr Prayers in Arafat Holy Site    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



FDA panel endorses booster shot for J&J COVID-19 vaccine
Published in The Saudi Gazette on 16 - 10 - 2021

A panel of experts voted unanimously to recommend that the Food and Drug Administration authorize a booster dose of the Johnson & Johnson COVID-19 vaccine. US health advisors endorsed the booster vaccine Friday, citing concern that Americans who got the single-dose shot aren't as protected as those given two-dose brands.
In a 19-0 vote, the panel recommended that the booster dose come at least two months after initial immunization with one shot of the J&J vaccine. It applies to people 18 years and older.
During the meeting, J&J presented data that showed the protection of the single shot remained largely stable over time but that a second dose pushed protection to a higher level.
Dr. Peter Marks, director of FDA's Center for Biologics Evaluation and Research, said the morning's presentations by J&J didn't include other relevant information about why a booster might be valuable after the initial immunization.
"There are data suggesting the effectiveness of the vaccine is actually less robust than the company's presentation here," he said.
Marks then called on Dr. Amanda Cohn, a panelist who is also chief medical officer of the National Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention.
She cited a study published by the CDC in September that showed the J&J vaccine had effectiveness of around 68% in keeping people out of the hospital for COVID-19 compared with more than 90% for Moderna's vaccine and about 77% for the Pfizer-BioNTech after about four months.
Cohn said the J&J vaccine's protection was substantially lower than the mRNA vaccines made by Moderna and Pfizer — even when waning of their protection is taken into account.
J&J told the Food and Drug Administration that an extra dose adds important protection as early as two months after initial vaccination — but that it might work better if people wait until six months later.
Unable to settle the best timing, the FDA's advisory panel voted unanimously that the booster should be offered at least two months after people got their earlier shot.
"I think this frankly was always a two-dose vaccine," said FDA adviser Dr. Paul Offit of Children's Hospital of Philadelphia. "It would be hard to recommend this as a single-dose vaccine at this point."
The FDA isn't bound by the recommendation as it makes a final decision — and adding to the debate's complexity, new research also suggests that J&J recipients might have a stronger immune response if their booster dose is from a competing brand.
Preliminary results from an ongoing study of different ways to "mix and match" different shots showed that a booster of any sort revved up people's levels of virus-fighting antibodies — at least for a few weeks. And the most dramatic jump came from giving a Pfizer or Moderna shot after the single-dose J&J vaccination.
FDA's advisers didn't vote on whether that should be recommended but told the government to allow flexibility with boosters, saying there were no safety red flags even if it's not yet clear just how much difference, if any, mixing and matching may make in long-term protection.
"In the real world all these kind of combinations are already happening so I think it's a matter of some urgency for the FDA to help sort out what is admittedly a complicated and challenging scenario," said Dr. Ofer Levy of Boston Children's Hospital.
Last month Pfizer boosters started being offered to seniors and younger adults at high risk from COVID-19 because of poor health, jobs or living conditions — at least six months after their initial vaccination. Thursday, the FDA advisory panel recommended the same approach for half-dose Moderna boosters.
"This is really -- with the second dose -- bringing it, I think, on par with those other vaccines in terms of effectiveness," said Dr. Archana Chatterjee of Rosalind Franklin University.
The FDA will use its advisers' recommendations to decide whether to authorize boosters for both J&J and Moderna. Next, the Centers for Disease Control and Prevention would rule on who should roll up their sleeves.
The J&J vaccine was highly anticipated for its one-and-done formulation. But its rollout earlier this year was hurt by a series of troubles including manufacturing problems and some rare but serious side effects including a blood clot disorder and a neurological reaction called Guillain-Barre syndrome. In both cases, regulators decided the shot's benefits outweighed those risks. — Agencies


Clic here to read the story from its source.